These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 22506598

  • 1. Detection of anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer and related issues in ALK inhibitor therapy: a literature review.
    Yi ES, Chung JH, Kulig K, Kerr KM.
    Mol Diagn Ther; 2012 Jun 01; 16(3):143-50. PubMed ID: 22506598
    [Abstract] [Full Text] [Related]

  • 2. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
    Cancer Treat Rev; 2014 Mar 01; 40(2):300-6. PubMed ID: 23931927
    [Abstract] [Full Text] [Related]

  • 3. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
    Casaluce F, Sgambato A, Sacco PC, Palazzolo G, Maione P, Rossi A, Ciardiello F, Gridelli C.
    Curr Clin Pharmacol; 2016 Mar 01; 11(2):77-87. PubMed ID: 27138017
    [Abstract] [Full Text] [Related]

  • 4. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
    Ou SH.
    Drug Des Devel Ther; 2011 Mar 01; 5():471-85. PubMed ID: 22162641
    [Abstract] [Full Text] [Related]

  • 5. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
    Di Maio M, De Marinis F, Hirsch FR, Gridelli C.
    Int J Oncol; 2014 Aug 01; 45(2):509-15. PubMed ID: 24859689
    [Abstract] [Full Text] [Related]

  • 6. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.
    Hembrough T, Liao WL, Hartley CP, Ma PC, Velcheti V, Lanigan C, Thyparambil S, An E, Monga M, Krizman D, Burrows J, Tafe LJ.
    Clin Chem; 2016 Jan 01; 62(1):252-61. PubMed ID: 26585927
    [Abstract] [Full Text] [Related]

  • 7. Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
    Karachaliou N, Santarpia M, Gonzalez Cao M, Teixido C, Sosa AE, Berenguer J, Rodriguez Capote A, Altavilla G, Rosell R.
    Expert Opin Investig Drugs; 2017 Jun 01; 26(6):713-722. PubMed ID: 28463570
    [Abstract] [Full Text] [Related]

  • 8. Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions.
    Cameron L, Solomon B.
    Drugs; 2015 Jul 01; 75(10):1059-70. PubMed ID: 26076736
    [Abstract] [Full Text] [Related]

  • 9. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
    Toyokawa G, Seto T.
    Clin Lung Cancer; 2014 Sep 01; 15(5):313-9. PubMed ID: 24984564
    [Abstract] [Full Text] [Related]

  • 10. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D, Wang Z, Yang L, Mu X, Wang Y, Zhao X, Li J, Lin D.
    Oncotarget; 2016 Sep 27; 7(39):64410-64420. PubMed ID: 27418132
    [Abstract] [Full Text] [Related]

  • 11. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.
    Camidge DR, Theodoro M, Maxson DA, Skokan M, O'Brien T, Lu X, Doebele RC, Barón AE, Varella-Garcia M.
    Cancer; 2012 Sep 15; 118(18):4486-94. PubMed ID: 22282074
    [Abstract] [Full Text] [Related]

  • 12. Testing for anaplastic lymphoma kinase rearrangement to target crizotinib therapy: oncology, pathology and health economic perspectives.
    Lee JA, Bubendorf L, Stahel R, Peters S.
    Expert Rev Anticancer Ther; 2013 May 15; 13(5):625-36. PubMed ID: 23617353
    [Abstract] [Full Text] [Related]

  • 13. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S, Villaruz LC, Abberbock S, Mahaffey A, Incharoen P, Nikiforova MN.
    Oncotarget; 2016 Dec 13; 7(50):82943-82952. PubMed ID: 27769042
    [Abstract] [Full Text] [Related]

  • 14. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
    Sgambato A, Casaluce F, Maione P, Gridelli C.
    Expert Rev Anticancer Ther; 2018 Jan 13; 18(1):71-80. PubMed ID: 29187012
    [Abstract] [Full Text] [Related]

  • 15. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R, Varella-Garcia M, Li M, Ludkovski O, Danesh A, Ng C, Pham NA, Pugh T, Shepherd FA, Tsao MS.
    J Thorac Oncol; 2016 Dec 13; 11(12):2248-2252. PubMed ID: 27613526
    [Abstract] [Full Text] [Related]

  • 16. ALK in lung cancer: past, present, and future.
    Shaw AT, Engelman JA.
    J Clin Oncol; 2013 Mar 10; 31(8):1105-11. PubMed ID: 23401436
    [Abstract] [Full Text] [Related]

  • 17. Crizotinib and testing for ALK.
    Shaw AT, Solomon B, Kenudson MM.
    J Natl Compr Canc Netw; 2011 Dec 10; 9(12):1335-41. PubMed ID: 22157554
    [Abstract] [Full Text] [Related]

  • 18. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
    Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR.
    Lancet Oncol; 2011 Oct 10; 12(11):1004-12. PubMed ID: 21933749
    [Abstract] [Full Text] [Related]

  • 19. Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer.
    Croegaert K, Kolesar JM.
    Am J Health Syst Pharm; 2015 Sep 01; 72(17):1456-62. PubMed ID: 26294238
    [Abstract] [Full Text] [Related]

  • 20. The molecular detection and clinical significance of ALK rearrangement in selected advanced non-small cell lung cancer: ALK expression provides insights into ALK targeted therapy.
    Zhang NN, Liu YT, Ma L, Wang L, Hao XZ, Yuan Z, Lin DM, Li D, Zhou YJ, Lin H, Han XH, Sun Y, Shi Y.
    PLoS One; 2014 Sep 01; 9(1):e84501. PubMed ID: 24404167
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.